JP5774607B2 - 体外治療による毒性因子の除去 - Google Patents

体外治療による毒性因子の除去 Download PDF

Info

Publication number
JP5774607B2
JP5774607B2 JP2012552160A JP2012552160A JP5774607B2 JP 5774607 B2 JP5774607 B2 JP 5774607B2 JP 2012552160 A JP2012552160 A JP 2012552160A JP 2012552160 A JP2012552160 A JP 2012552160A JP 5774607 B2 JP5774607 B2 JP 5774607B2
Authority
JP
Japan
Prior art keywords
blood
toxin
substrate
beads
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012552160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518687A5 (enExample
JP2013518687A (ja
Inventor
マクリア，キース
ワード，ロバート・エス
Original Assignee
エクステラ・メディカル・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクステラ・メディカル・コーポレーション filed Critical エクステラ・メディカル・コーポレーション
Publication of JP2013518687A publication Critical patent/JP2013518687A/ja
Publication of JP2013518687A5 publication Critical patent/JP2013518687A5/ja
Application granted granted Critical
Publication of JP5774607B2 publication Critical patent/JP5774607B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • External Artificial Organs (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012552160A 2010-02-09 2011-02-09 体外治療による毒性因子の除去 Active JP5774607B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30282610P 2010-02-09 2010-02-09
US61/302,826 2010-02-09
PCT/US2011/024229 WO2011100354A1 (en) 2010-02-09 2011-02-09 Removal of virulence factors through extracorporeal therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015044951A Division JP2015131831A (ja) 2010-02-09 2015-03-06 体外治療による毒性因子の除去

Publications (3)

Publication Number Publication Date
JP2013518687A JP2013518687A (ja) 2013-05-23
JP2013518687A5 JP2013518687A5 (enExample) 2014-07-17
JP5774607B2 true JP5774607B2 (ja) 2015-09-09

Family

ID=43975201

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012552160A Active JP5774607B2 (ja) 2010-02-09 2011-02-09 体外治療による毒性因子の除去
JP2015044951A Pending JP2015131831A (ja) 2010-02-09 2015-03-06 体外治療による毒性因子の除去

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015044951A Pending JP2015131831A (ja) 2010-02-09 2015-03-06 体外治療による毒性因子の除去

Country Status (9)

Country Link
US (1) US20120305482A1 (enExample)
EP (1) EP2533828B1 (enExample)
JP (2) JP5774607B2 (enExample)
KR (1) KR101486879B1 (enExample)
CN (1) CN102791307B (enExample)
AU (1) AU2011215942B8 (enExample)
CA (1) CA2786550C (enExample)
ES (1) ES2728122T3 (enExample)
WO (1) WO2011100354A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029958T2 (en) 2005-12-13 2017-04-28 Exthera Medical Corp A method for removing extracellular microbes, inflammatory cells or inflammatory proteins from the body
WO2008155683A1 (en) 2007-06-18 2008-12-24 Firmenich Sa Malodor counteracting compositions and method for their use
JP5925693B2 (ja) 2009-12-01 2016-05-25 エクステラ・メディカル・コーポレーション 表面固定した多糖類を用いた、血液からのサイトカイン除去法
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
DK2861273T3 (da) 2012-06-13 2017-11-27 Exthera Medical Corp Anvendelse af heparin og kulhydrater til behandling af cancer.
ES2996347T3 (en) * 2012-06-29 2025-02-12 Cytosorbents Corp Biocompatible sorbent
EP3013445B1 (en) * 2013-06-24 2019-11-06 ExThera Medical Corporation Blood filtration system containing mannose coated substrate
JP6806563B2 (ja) 2013-11-08 2021-01-06 エクステラ・メディカル・コーポレーション 吸着媒体を使用する感染症の診断法
KR20170020749A (ko) 2014-04-24 2017-02-24 엑스테라 메디컬 코퍼레이션 고유속을 이용한 혈액으로부터 세균의 제거방법
JP7100454B2 (ja) 2014-09-22 2022-07-13 エクスセラ メディカル コーポレイション 装着型血液潅流デバイス
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
WO2017151797A1 (en) 2016-03-02 2017-09-08 Exthera Medical Corporation Method for treating drug intoxication
US10822461B2 (en) 2017-10-05 2020-11-03 Fresenius Medical Care Holdings, Inc. Polysulfone-urethane copolymer, membranes and products incorporating same, and methods for making and using same
EP3735281B1 (en) 2018-01-05 2024-11-27 Path Ex, Inc. Device for the capture and removal of disease material from fluids
KR20220009400A (ko) 2019-05-16 2022-01-24 엑스테라 메디컬 코퍼레이션 내피 글리코칼릭스 구조의 조절 방법
EP4251230A1 (en) * 2020-11-30 2023-10-04 Alteco Medical AB Device for binding and separation of at least one component from a body fluid
HUP2200216A1 (hu) 2022-06-15 2023-12-28 Captec Medical Kft Nagy teljesítményû, immun-affinitáson alapuló, extrakorporális patogén csapda

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916352A1 (de) * 1999-04-12 2000-10-19 Braun Melsungen Ag Entfernung von hüllehaltigen Viren aus Blut, Plasma oder Serum
US6803183B2 (en) * 2002-07-18 2004-10-12 Clarigen, Inc. Method for removing pyrogens from plasma and blood for treatment of septic shock
RU2353399C2 (ru) * 2003-01-17 2009-04-27 Этлон Медикал, Инк. Способ удаления вирусов из крови посредством лектин-аффинного гемодиализа
CA2581883A1 (en) * 2004-09-27 2006-04-06 Technion Research & Development Foundation Ltd. Novel antimicrobial agents
HUE029958T2 (en) * 2005-12-13 2017-04-28 Exthera Medical Corp A method for removing extracellular microbes, inflammatory cells or inflammatory proteins from the body
CA2690401C (en) * 2007-06-18 2016-10-18 Olle Larm Device and method for restoration of the condition of blood

Also Published As

Publication number Publication date
CN102791307A (zh) 2012-11-21
CA2786550A1 (en) 2011-08-18
AU2011215942B8 (en) 2014-02-13
CA2786550C (en) 2018-03-13
KR101486879B1 (ko) 2015-01-28
KR20120123692A (ko) 2012-11-09
JP2015131831A (ja) 2015-07-23
EP2533828A1 (en) 2012-12-19
CN102791307B (zh) 2016-05-18
AU2011215942A1 (en) 2012-07-26
EP2533828B1 (en) 2019-02-27
JP2013518687A (ja) 2013-05-23
WO2011100354A1 (en) 2011-08-18
AU2011215942B2 (en) 2014-01-30
ES2728122T3 (es) 2019-10-22
US20120305482A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
JP5774607B2 (ja) 体外治療による毒性因子の除去
US11123466B2 (en) Methods for removing cytokines from blood with surface immobilized polysaccharides
US10537280B2 (en) Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
HK1176572A (en) Removal of virulence factors through extracorporeal therapy
HK1176572B (en) Removal of virulence factors through extracorporeal therapy
AU2014277852B2 (en) Method for removing cytokines from blood with surface immobilized polysaccharides
HK1177151B (en) Method for removing cytokines from blood with surface immobilized polysaccharides

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140509

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150306

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150701

R150 Certificate of patent or registration of utility model

Ref document number: 5774607

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250